sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY May 2017 | Archived Issues

FDA Issues Warning Against Canagliflozin

The U.S. Food and Drug Administration (FDA) is warning Type 2 diabetes patients who take canagliflozin that the medicine can cause an increased risk of leg and foot amputations.

Two recent large clinical trials showed that leg and foot amputations occurred about twice as often in patients treated with canagliflozin as in patients treated with a placebo.

Patients taking canagliflozin should contact their healthcare provider immediately if new pain, tenderness, sores, ulcers, or infections develop in the legs or feet.

The FDA website has more information.